期刊文献+

密码子优化的HIV-1型gp120基因重组腺病毒载体疫苗的构建与鉴定

CONSTRUCTION AND CHARACTERIZATION OF A CODON OPTIMIZED HIV-1 GP120 GENE RECOMBINANT ADENOVIRUS VECTOR
下载PDF
导出
摘要 目的构建密码子优化型gp120基因重组腺病毒载体(rAden-mgp120),为研发新型HIV预防性疫苗奠定基础。方法首先利用PCR的方法扩增mgp120基因,将目的基因克隆入载体pENTR/D-TOPO以获得重组穿梭载体克隆pENTR/D-TOPO-mgp120。经过穿梭载体克隆与表达载体(pAd-CMV/V5-DEST)间的重组反应获得表达克隆质粒pAden-mgp120,表达克隆线性化后转染HEK293A包装细胞,得到复制缺陷型重组腺病毒rAden-mgp120。结果经PCR和测序鉴定,重组载体rAden-mgp120构建正确,转染HEK293A细胞并扩增后获得的病毒滴度为6.8x1010pfu/ml,该重组腺病毒载体能正确表达mgp120蛋白。结论成功构建了重组腺病毒rAdenmgp120为HIV-1预防奠定了基础。 Objective To generate recombinant adenoviral vector containing mgp120 gene for developing a safe, effective vaccine. Methods The mgp120 gene was cloned into pENTR/D-TOPO transfer vector after the base pairs of DNA (CACC) sequence was added to th'e 5' end. Adenoviral expression vector containing mgp120 gene was constructed by homologous recombination. The linearized DNA plasmid of the recombi- nant adenoviral vector was transfected human embryo kidney (HEK) 293A cells to package and amplify re- combinant adenovirus. The recombinant adenovirus titer was characterized by using the End-dilution as- say. The expression of the mgp120 protein in 293A cells was detected by Western blot. Results The construction of mgp120 gene recombinant pENTR/D-TOPO transfer vector was successful. The recombinant adenoviral vector, Aden-mgpl20, was generated successfully, too. The titer of Aden-mgp120 was characterized as 6.8)〈 101~pfu/mL. The mgp120 protein was expressed by HEK 293A cells correctly. Conclusion The mgp120 gene recombinant replication-defective adenovirus expression vector was constructed successfully and this study has provided an experimental basis for further research on HIV-1 vaccine.
出处 《山东医学高等专科学校学报》 2014年第1期31-33,F0002,共4页 Journal of Shandong Medical College
基金 山东省卫生厅医药卫生科技发展计划项目(NO.2009HW087) 山东省教育厅高校科技发展计划项目(NO.J07YE06)
关键词 人类免疫缺陷病毒I型 gp120基因 重组腺病毒载体 疫苗 HIV-1 gpl20 gene Recombinant Adenovirus vector Vaccine
  • 相关文献

参考文献10

  • 1Anthony S. Fauci, Margaret I. Johnston, Carl W. Dieffenbach, et al. HIV Vaccine Research: The Way Forward[J]. Science, 2008, 321: 530-532.
  • 2Wang, S., Farfan-Arribas, D.J., Shen, S., Chou, T. H. , et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenieity of HIV-1 Env DNA vaecine[J]. Vaccine, 2006,24 (21).. 4531-4540.
  • 3Abdel-Motal, U., Wang, S., Lu, S., et al. In- creased Immunogenicity of Human Immunodefieieney Virus gp120 Engineered To Express Gal{ alpha} 1-3Gal {beta}l 4GlcNAc-R Epitopes[J]. J Virol, 2006, 80 (14) :6943-6951.
  • 4刘瑞林,马永臻,张永东,马春玲.HPV16-E7 H2P融合钙网蛋白基因重组腺病毒载体疫苗的构建与免疫学鉴定[J].山东医学高等专科学校学报,2012,34(5):321-324. 被引量:1
  • 5Wyatt R. The ITIIV-1 envelope glycoproteins : fusogens, antigens, and immunogens [J]. Science, 1998, 280; 1884-1889.
  • 6Wang SX, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of Human Immu- nodeficiency Virus Type 1[J]. Gene Ther,2005, 79: 7933-7937.
  • 7白雪,庞伟,王路,张高红,郑永唐.HIV-1 C亚型密码子优化gp120基因重组腺病毒载体的构建及表达[J].医学分子生物学杂志,2009,6(5):397-400. 被引量:2
  • 8Li Y, Luo L, Thomas DY, Kang CY. The HIV-1 Env protein signal sequence retards its cleavage and down- regulates the glycoprotein folding[J]. Virology 2000; 272(2) =417-428.
  • 9Smith AE. Viral vectors in gene therapy[J]. Annu Rev Microbial, 1995,49 = 807-838.
  • 10D. H. Barouch and CJ. Nabal , Adenovirus vector- based vaccines for human Immunodeficiency Virus type 1. Hum[J]. GeneTher,2005,16:149-156.

二级参考文献32

  • 1王路,白雪,刘红亮,张高红,郑永唐.重组腺病毒载体vAd-tat的构建及其在细胞中的表达[J].免疫学杂志,2009(2):168-172. 被引量:7
  • 2MCCUTCHAN F E.Understanding the genetic diversity of HIV-1[J].AIDS,2000,14:S31-44.
  • 3ESPARZA J,BHAMARAPRAVATI N.Accelerating the development and future availability of HIV-1 vaccines:why,when,where,and how?[J].Lancet,2000,355:2061-2066.
  • 4OSMANOV S,PATTOU C,WALKER N,et al.Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000[J].J Acquir Immune Defic Syndr,2002,29(2):184-190.
  • 5SMITA S,KULLKARNI,LAPEDES A,et al.Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India[J].Virology,2009,385(2):505-520.
  • 6MOVITSKY V,SMITH U R,CILBERT P,et al.Human immunodeficiency virus type 1 subtype C molecular phylogeny:consensus sequence for an AIDS vaccine design?[J].J Virol,2002,76(11):5435-5451.
  • 7JOSEPH P N,ESSEX M.Progress towards an HIV-1 subtype C vaccine[J].Vaccine 2006,24(4):391-401.
  • 8PWHI P,GAUDUIN M C,KOUP R A,et al.Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design[J].Immunol Lett,1997,58:125-132.
  • 9LI B,DECKER J M,JOHNSON R W,et al.Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1[J].J Virology,2006,80(11):5211-5218.
  • 10RADEMEYER C,MOORE P L,TAYLOR N,et al.Genetic characteristics of HIV-1subtype C envelopes inducing cross-neutralizing antibodies[J].Virology,2007,368(1):172-181.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部